Allena leans into $92m IPO

Allena Pharmaceuticals, a Pharmstandard-backed developer of metabolic and kidney disorder treatments, has filed to go public after raising $93m in venture capital.

Author: Robert Lavine, News Editor

Allena Pharmaceuticals, a US-based developer of treatments for metabolic and kidney disorders, has filed to raise up to $92m in an initial public offering that will allow pharmaceutical company Pharmstandard to exit.

This rest of this content is only accessible to Global Corporate Venturing Subscribers

This content is only accessible to subscribers. If you are a subscriber,
please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.